在人类肝脏显微体中,多尼佩西尔和塔达拉菲尔之间的P450细胞染色体介导的代谢相互作用
Jieun Yu1, Ji Hyeon Ryu1, Yong Ha Chi2
1College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
概括
塔达拉菲尔 (用于勃起功能障碍) 可以通过抑制CYP3A4.4来增加多尼佩西尔 (用于痴呆症) 水平. 这种药物相互作用主要是由于tadalafil.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 药物相互作用 药物相互作用
背景情况:
- 多尼佩西尔和塔达拉菲尔通常分别用于痴呆症和勃起功能障碍.
- 这两种药物都主要通过细胞染色体P450 3A4 (CYP3A4) 代谢.
- 在此之前,多内和塔达拉菲尔之间潜在的药物相互作用 (DDI) 是未知的.
研究的目的:
- 为了评估donepezil和tadalafil之间的CYP介导的代谢相互作用.
- 为了预测这两种常见的处方药之间的DDI潜力.
- 调查塔达拉菲尔对多内佩西尔代谢的影响,反之亦然.
主要方法:
- 使用聚合的人类肝脏显微体 (HLMs) 来评估药物代谢.
- 测量了多尼佩西尔和塔达拉菲尔半衰期和代谢物形成率的变化.
- 通过计算IC50值和评估时间依赖性抑制来确定CYP3A4抑制.
主要成果:
- 塔达拉菲尔显著增加了多尼佩西尔的半衰期,达到32.3%,并减少了其代谢物形成.
- 多尼西尔没有显著改变塔达拉菲尔的半衰期或代谢物产生.
- 塔达拉菲尔表现出依赖时间的CYP3A4抑制,在预化后IC50降低了大约7.04倍.
结论:
- 多尼佩西尔和塔达拉菲尔之间的主要DDI是由塔达拉菲尔对CYP3A4.4的时间依赖抑制驱动的.
- 塔达拉菲尔对患者增加多尼佩西尔暴露的风险很大.
- 由于潜在的药理动力学相互作用,建议在同时开这类药物时谨慎使用.
相关概念视频
Drug Metabolism: Phase I Reactions
3.2K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.2K
Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
104
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
Factors Affecting Drug Biotransformation: Biological
128
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
128
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34


